GlobeNewswire PharmaOriginal article
Zentalis Pharmaceuticals Announces Pricing of Underwritten Public Offering
azenosertibNeutral
AI Analysis
Summary
Zentalis Pharmaceuticals announced pricing of an underwritten public offering of 23 million shares at $3.50 per share, raising approximately $80.5 million in gross proceeds. The offering is expected to close on August 17, 2026.
Importance:5/10
Sentiment:
0.00
public offeringequity financingoncologyWEE1 inhibitor
Related Companies
Read the original article
Published by GlobeNewswire Pharma on August 14, 2026 2:23 AM